Experimental cell therapy targets Hard-to-Treat leukemia
NCT ID NCT05739409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new cell therapy called LILRB4 STAR-T cells in one person with monocytic leukemia, a type of blood cancer. The goal was to see if the treatment is safe and can reduce cancer cells in the bone marrow. Researchers monitored side effects like cytokine release syndrome and checked for cancer remission after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Personalized leukemia vaccine aims to outsmart relapse